Enterprise Value
91.11M
Cash
14.71M
Avg Qtr Burn
N/A
Short % of Float
2.20%
Insider Ownership
13.20%
Institutional Own.
23.41%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZONISADE (Zonisamide) (ET-104) Details Rare genetic disease, Neurological disorder | Approved Update | |
Carbaglu® (carglumic acid tablets) Details Hyperammonemia NAGS deficient, chronic hyperammonemia | Approved Quarterly sales | |
Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) Details Itchy Eyes Associated with Allergies | Approved Quarterly sales | |
Biorphen® (phenylephrine HCI) Details Hypotension (vasodilation in the setting of anesthesia) | Approved Quarterly sales | |
EPRONTIA (Topiramate Oral Solution) (ET-101) Details Tonic-clonic seizures / seizures / migraine | Approved Quarterly sales | |
Rezipres (Ephedrine Injection) (ET-203) Details Injectable hospital-use product | Approved Quarterly sales | |
Cysteine hydrochloride injection (generic - ANDA) Details Additive to amino acid solutions to meet the nutritional requirements of newborn infants | Approved Quarterly sales | |
ALKINDI® SPRINKLE (hydrocortisone) Details Adrenocortical Insufficiency (Pediatrics) | Approved Quarterly sales | |
Dehydrated Alcohol Injection (DS-100) Details Methanol poisoning Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
ET 600 Details Rare diseases | NDA Submission | |
Lamotrigine Oral Suspension (ET-105) Details Lennox-Gastaut syndrome | NDA FDA meeting |